Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
How heart failure risk rises after surgery
Wed June 29th - The development of atrial fibrillation following surgery is an important risk factor for heart failure, researchers report today. More
Brain surgery benefits intracranial pressure
Wed June 29th - Craniectomy for intracranial hypertension offers significant benefit, according to new guidance, triggered by British research. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For books and family gift ideas click here
RSS graphic XML Graphic

Challenge to HRT-breast cancer link

Tuesday January 17th, 2012

A new challenge is made today to a landmark British study which helped discredit the use of hormone replacement therapy by women.

A group of international experts claims the Million Women study, which linked HRT to breast cancer, was flawed.

Writing in the Journal of Family Planning and Reproductive Health Care, the researchers claim the analysis was flawed.

The British-based study was run in parallel with major research elsewhere, such as the US-based Womens Health Initiative.

Its findings on HRT and breast cancer were reported in 2004. It also found link with endometrial and ovarian cancer.

The research suggested that the combined oestrogen-progestagen treatment doubled breast cancer risk. The latest findings were published last August.

But now Professor Samuel Shapiro, of the University of Cape Town Medical School, South Africa, and four other experts from the UK, Australia and Germany claims the research is flawed - mainly because it used women undergoing breast screening.

The experts all admit they have acted as consultants to HRT manufacturers - and mostly still do.

Professor Shapiro says the rates of breast cancer among all the women studied - including those not on HRT - were higher than normal as a result. And, he suggests, this is partly because women worried by existing lumps are more likely to agree to undergo breast screening.

He states: "Breast cancer can sometimes grow slowly, and remain undetected for years. Even a small bias resulting in the detection of one to 1.2 extra cases each year among 1000 women who had used HRT for five years, or an extra 1.5 to 1.9 cases in those using HRT for 10 years, would have invalidated the overall findings."

He adds: "The name Million Women Study implies an authority beyond criticism or refutation.

"Many commentators, and the investigators, have repeatedly stressed that it was the largest study of HRT and breast cancer ever conducted.

"Yet the validity of any study is dependent on the quality of its design, execution, analysis and interpretation. Size alone does not guarantee that the findings are reliable."

* In their report last August the original study's authors said there was a clear pattern of risk following the adoption of HRT - with risk levels returning to normal when women gave up the treatment.

The Journal of Family Planning and Reproductive Health Care January 17 2012 doi: 10.1136/jfprhc-2011-100229

Tags: Africa | Australia | Cancer | Europe | Pharmaceuticals | UK News | Women’s Health & Gynaecology

Printer friendly page Printer friendly page